Early Development Still Driving CRO Performance

More and more contract manufacturers have been looking not at what the state of the supply chain is right now, but what it may be in the next three to five years.

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

The company now performs product-sterility testing through rapid microbiological methods at two laboratory sites in the United States and one in Germany.

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Sponsor companies and contract development and manufacturing companies must ensure that the suppliers they use are following sustainability guidelines to truly produce ‘green’ products.

Contractors are working with sponsor companies to establish and maintain sustainable manufacturing practices in pharma.